Your browser doesn't support javascript.
loading
Effects of simvastatin, pentoxifylline and spironolactone on hepatic fibrosis and portal hypertension in rats with bile duct ligation.
Oberti, F; Pilette, C; Rifflet, H; Maïga, M Y; Moreau, A; Gallois, Y; Girault, A; le Bouil, A; Le Jeune, J J; Saumet, J L; Feldmann, G; Calès, P.
Afiliación
  • Oberti F; Laboratoire d'Hémodynamique Splanchnique, UFR de Médecine, Université d'Angers, France.
J Hepatol ; 26(6): 1363-71, 1997 Jun.
Article en En | MEDLINE | ID: mdl-9210625
ABSTRACT
AIMS/

METHODS:

Our aim was to study the antifibrotic and hemodynamic effects of simvastatin (SMV), pentoxifylline (PTX) and spironolactone (SPN), three drugs which may have antifibrotic and/or portal hypotensive properties, in a model of hepatic fibrosis and portal hypertension induced in rats by bile duct ligation. A blind study was performed in five groups of 53 Sprague-Dawley rats sham, placebo (PL), SMV (2.5 mg x kg(-1) x J(-1)), PTX (50 mg x kg(-1) x J(-1)) and SPN (100 mg x kg(-1) x J(-1)). Drugs were administered by daily gavage over a 4-week period as soon as bile duct ligation was performed. At day 28, the following parameters were evaluated area of hepatic fibrosis by image analysis after staining collagen with picrosirius and plasma concentrations of hyaluronate, splanchnic and systemic hemodynamics (radiolabeled microspheres).

RESULTS:

Portal venous pressure (PL 15.5+/-1.5, SMV 15.8+/-2.5, PTX 15.9+/-1.8, SPN 13.5+/-2.1 mmHg, p<0.05) and porto-systemic shunts (PL 30+/-31, SMV 18+/-27, PTX 25+/-24, SPN 5+/-4%, p<0.05) were significantly reduced in the SPN group; other hemodynamic parameters were not significantly altered. There was a significant correlation between portosystemic shunts and portal pressure (r(s)=0.47, p<0.01). The area of fibrosis was not significantly different among the four groups of bile duct ligated rats (PL 8.7+/-3.9, SMV 7.1+/-3.6, PTX 7.8+/-2.7, SPN 6.6+/-3.3%) but was higher than in sham rats (1.5+/-0.5%, p<0.001). Hyaluronate was significantly higher in bile duct ligated rats (from 374+/-162 to 420+/-131 microg/l, among the four groups) than in sham rats (52+/-16 microg/l, p<0.0001).

CONCLUSIONS:

In this model, none of the drugs prevented hepatic fibrosis. On the other hand, spironolactone decreased portal pressure and prevented porto-systemic shunts. Therefore, this drug may have beneficial effects in patients with early portal hypertension.
Asunto(s)
Buscar en Google
Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Pentoxifilina / Espironolactona / Lovastatina / Hemodinámica / Hipertensión Portal / Cirrosis Hepática Experimental / Hipolipemiantes Límite: Animals Idioma: En Revista: J Hepatol Asunto de la revista: GASTROENTEROLOGIA Año: 1997 Tipo del documento: Article País de afiliación: Francia
Buscar en Google
Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Pentoxifilina / Espironolactona / Lovastatina / Hemodinámica / Hipertensión Portal / Cirrosis Hepática Experimental / Hipolipemiantes Límite: Animals Idioma: En Revista: J Hepatol Asunto de la revista: GASTROENTEROLOGIA Año: 1997 Tipo del documento: Article País de afiliación: Francia